The House Appropriations Committee announced the Omnibus Appropriations bill providing the FDA more funding this year for medical product safety initiatives. Funding is also directed to the Combating Antibiotic Resistant Bacteria (CARB) initiative, the Precision Medicine Initiative and the Orphan Product Development Grants Program.
The NIH will also receive more funding for Alzheimer’s disease research, brain research, antibiotic research and the Precision Medicine Initiative. An increase in funding will also be available for biomedical and translational research.
The additional funding from this bill means a victory for those patients waiting.
For more information, please read Melissa Fassbender’s entire article at in-Pharma. Pearl Pathways always has the patient in mind – contact us for help in accelerating your product development.